



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kenten et al. Application No.: 09/964,201

Filing Date: September 26, 2001

Title: UBIQUITIN FUSION-BASED VACCINE SYSTEM

Art Unit: Not yet assigned Examiner: Not yet assigned

Docket No.: IGN-2005

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Honorable Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

KEVIN M. FARRELL, P.C.

RESPONSE TO NOTICE TO COMPLY

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

Sir:

On April 19, 2002, a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (referred to herein as Notice to Comply) was mailed from the Patent Office. In response, please find enclosed replacement Sequence Listing in paper form, and on diskette.

B

REMARKS

Attached is a paper copy of the Sequence Listing prepared in accordance with the provisions of 37 CFR 1.825(d). Instruction for amendment of the Specification to incorporate the Sequence Listing was filed with the Patent Office on December 6, 2001, in response to the Notice to Comply.

Also transmitted herewith is a copy of the Sequence Listing in computer readable form. As required by 37 CFR 1.821 (e) or 1.821 (f) or 1.821 (g) or 1.825 (c) or 1.825 (d), Applicant's Attorney hereby states that the content of the Sequence Listing in paper form and computer readable form are the same and include no new matter.

Respectfully submitted,

Kevin M. Farrell

Attorney for Applicants

Registration No.: 35,505

(207) 363-0558

Dated: 5\B\S\
York Harbor, Maine

IGN\ARC\2005.AM2

B